In my opinion, one of the greatest threats to the specialty of pathology is the "insourcing" of pathology specimens by large clinical practice groups, usually urologists and gastroenterologists. I have posted previous notes about this practice in which I have referred to the construction of in-office histopathology labs (see: Pathologist Satisfaction with "Pod Lab" Positions; Corrected Definition for a Pod Lab and a Look at In-Office Labs). The basic concept is that the clinical groups processes their own tissue specimens and then contract with a pathologists to generate the interpretive reports. Fees for both the technical and professional components are collected by the group.
The Pathology Business Institute is offering a webinar entitled Fight Back Against the Insourcing of Pathology Specimens on Monday, June 14, at 3:00 - 4:00 p.m. EST. with three faculty members. Registration is limited to 50 participants. I very much like their adoption of the term "specimen insourcing" and will use it myself in the future. Obviously, building an in-office lab is the means by which the clinical groups are able to pursue this business model.
By the way, I have the distinct sense that our various national pathology societies have been curiously and conspicuously quiet on this issue. I would very much like to be disabused of this idea. Can any of the readers of Lab Soft News point me in the direction of high-level, broad-impact policy statements or seminars by our societies devoted to specimen insourcing? If none are to be found, can someone explain to me why this is the case?